Why is FITC-labeled full-length CD20 protein an ideal probe for B cell immunology research?

FITC-labeled full-length CD20 membrane protein integrates the convenience of fluorescent tracing with the intact conformation of the full-length protein, providing a reliable probe for flow cytometry detection, CAR-T positivity rate assessment, and therapeutic antibody screening. This article analyzes the intrinsic logic behind its emergence as a key tool in B cell research from three dimensions: labeling technology, conformational integrity, and experimental applications.

  • Recent Advances
  • Product Information
Recent Advances

 

Why Is FITC-Labeled Full-Length CD20 Protein an Ideal Probe for B-Cell Immunology Research?
Summary: FITC-labeled full-length CD20 membrane protein combines the convenience of fluorescent tracing with the intact conformation of the full-length protein, providing a reliable probe for flow cytometry detection, CAR-T positive rate assessment, and therapeutic antibody screening. This article analyzes the intrinsic logic behind its emergence as a key tool in B-cell research from three dimensions: labeling technology, conformational integrity, and experimental applications.
I. What Key Advantages Does FITC Labeling Technology Bring to Membrane Protein Visualization Research?
Fluorescein isothiocyanate (FITC), as a classic organic fluorescent dye, has a maximum excitation wavelength of 488 nm and a maximum emission wavelength of 518 nm, which exactly matches the most widely used blue laser in flow cytometers. Through standard chemical labeling methods, FITC covalently conjugates the fluorescent group to the primary amine groups on the side chains of protein lysine residues and the N-terminus. After purification by molecular sieving to remove free dye, a functional fluorescent protein suitable for direct flow analysis is obtained. Compared with the cumbersome two-step incubation of primary and fluorescent secondary antibodies in indirect immunofluorescence, FITC directly labeled CD20 protein can complete target cell binding and signal detection in one step, significantly shortening experimental time and reducing cell loss and signal variation caused by multiple washing steps. Meanwhile, uniform fluorescent labeling ensures batch-to-batch consistency, making quantitative comparisons between different experimental batches possible. In scenarios requiring precise quantification of positive rates such as CAR-T, this uniformity and convenience constitute an irreplaceable technical foundation.
II. Why Is Full-Length CD20 Protein Closer to Real Biological Scenarios Than Peptide Fragments?
CD20 is a four-transmembrane B lymphocyte-specific surface antigen, whose extracellular domains consist of the first extracellular loop (ECL1) and the second extracellular loop (ECL2), which cooperatively fold in space to form complete functional epitopes. Recent structural biology research breakthroughs have revealed that therapeutic antibody recognition of CD20 depends not only on the primary epitope on ECL2 but also requires the participation of a secondary epitope formed jointly by ECL1-ECL2 to achieve nanomolar-level affinity. Surface plasmon resonance (SPR) experiments further confirmed that the binding affinity of full-length CD20 to antibodies is far higher than that of the isolated ECL2 peptide, indicating that the spatial synergy of ECL1-ECL2 plays a decisive role in high-affinity binding. Using peptide fragments as detection probes would not only lose the conformational information of the ECL1-ECL2 secondary epitope but also alter the natural orientation of the extracellular loop region due to the lack of anchoring support from the complete transmembrane domain. Full-length CD20 protein, by virtue of its complete topological structure and post-translational modifications, maximally simulates the natural state of the B-cell membrane surface in detergent micelle or nanodisc systems, and the binding data it provides is truly physiologically relevant.
III. What Role Does FITC-Labeled Full-Length CD20 Protein Play in CAR-T Positive Rate Detection and Antibody Screening?
In the CAR-T cell therapy development process, accurate determination of CAR positive rate is a core step for quality control release. By directly incubating FITC-labeled full-length CD20 protein with CAR-T cells and quantifying the fluorescent signal via flow cytometry, the CAR expression ratio and distribution uniformity can be rapidly obtained. The ECL1-ECL2 conformational epitope fully presented by the full-length protein ensures the correlation between detection signals and the actual in vivo targeting capability of CAR-T cells, avoiding false negatives or weak binding caused by incomplete epitopes of peptide probes. In therapeutic antibody screening, FITC-CD20 full-length protein can simultaneously serve cell-based flow binding assays and microplate-based ELISA screening, allowing researchers to monitor the binding kinetics and specificity of antibodies to native conformational CD20 in real time. Furthermore, when validating the effects of mutation sites on binding in antibody engineering, FITC-labeled full-length protein, as a ready-to-use probe, provides a standardized, high-throughput evaluation method for parallel comparison of large numbers of candidate molecules, powerfully advancing R&D efficiency from hit screening to lead optimization.
Conclusion
The fluorescent labeling tool for full-length CD20 membrane protein provides an experimental solution combining conformational integrity and operational convenience for B-cell targeted drug development. Uia provides FITC-Labeled CD20 Flag&His Tag Full Length Protein, Human (Detergent), which maintains the natural four-transmembrane conformation of full-length CD20 in a detergent system and is suitable for flow cytometry detection, SPR affinity measurement, antibody screening, and other application scenarios.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Target proteins | membrane proteins | cytokines | enzymes | viral antigens | protein customization
Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience
Nanjing UNIV Biotechnology Co., Ltd. Email:order@ua-bio.com Phone:+86-25-56221161
公众号
Product Information
The Last The Next